Capecitabine (Xeloda®)

DRUG3 trials

Sponsors

Hoffmann-La Roche, National Cancer Center, Korea, Memorial Sloan Kettering Cancer Center

Conditions

Breast CancerPancreatic CancerRectal Cancer

Phase 2

A Study to Assess Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer

CompletedNCT00077857

Hoffmann-La RocheBreast Cancer

Start: 2003-07-31End: 2010-03-31Updated: 2013-05-10

Concurrent Chemo-radiotherapy With Capecitabine for Unresectable Locally Advanced Pancreatic Carcinoma

National Cancer Center, KoreaPancreatic Cancer

Start: 2006-06-30End: 2013-06-30Target: 55Updated: 2012-04-03

Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

Active, not recruitingNCT02008656

Memorial Sloan Kettering Cancer CenterRectal Cancer

Start: 2013-11-30End: 2026-11-30Updated: 2025-08-27

Related Papers

Ultrasensitive ctDNA monitoring for organ preservation in patients with locally advanced rectal cancer.

2025-12-11

No operation after short-course radiotherapy followed by consolidation chemotherapy in locally advanced rectal cancer (NOAHS-ARC): study protocol for a prospective, phase II trial.

2025-03-181 citations

MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer.

2024-09-015 citations

Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy

JAMA Network Open2024-01-0991 citations

Long-Term Results of Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The Randomized Phase II OPRA Trial

Journal of Clinical Oncology2023-10-26252 citations

Sustained organ preservation in patients with rectal cancer treated with total neoadjuvant therapy: Long-term results of the OPRA trial.

Journal of Clinical Oncology2023-06-0118 citations

Clinical and radiological predictors of organ preservation in patients with rectal cancer treated with total neoadjuvant therapy.

Journal of Clinical Oncology2022-06-018 citations

Survival and organ preservation according to clinical response after total neoadjuvant therapy in locally advanced rectal cancer patients: A secondary analysis from the organ preservation in rectal adenocarcinoma (OPRA) trial.

Journal of Clinical Oncology2021-05-2034 citations

Locally advanced rectal adenocarcinoma: Treatment sequences, intensification, and rectal organ preservation

CA A Cancer Journal for Clinicians2021-02-1621 citations

Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial.

Journal of Clinical Oncology2020-05-20220 citations

Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management

BMC Cancer2015-10-23379 citations